# NICE-UK Strategy 2021-2026 – PRECISIONheor Executive Summary

Recently, the National Institute for Health and Care Excellence (NICE) published a detailed **strategy plan**, outlining its vision during the next five years. Included in this report are new guidelines for technology evaluation, evidence standards, guidance adoption, and real-world data and research, which are applicable to all stakeholders, including the life science industry, regulators, healthcare providers, patients, and the public.

---

In this summary, PRECISIONheor Executive Vice President, Head of Medical Affairs Ross Maclean provides some key takeaways to life science innovators that help frame how NICE's strategic framework may impact their business:

- NICE has set a goal for "speeding up" the existing evaluation pathway—this may mean an even quicker technology appraisal process, which means companies would need to get their HEOR evidence package ready more quickly and start earlier. NICE has set a goal to undertake more technology assessments over the 2021-2026 period, and will start measuring the length of time it takes to appraise a new technology.

- NICE will be increasing its focus on medical technologies, diagnostics, genomic, and "hybrid" products. Typically, many of these products do not go through NICE; however, now that NICE is focusing more on these products, it may increase the need for health technology assessment (HTA) submissions outside of the traditional medicines. It appears that NICE will be carefully measuring the number of these assessments going forward.

- NICE wants to measure uptake of their guidance based on real-world data from the NHS and national audits—with an increased focus on who is actually listening and using NICE guidance, which in turn may mean that NICE guidance becomes more important.

- NICE is placing an increased focus on real-world data. (This is one that has been said for ages!) However, it looks like NICE now wants to measure the proportion of guidelines that are informed by real-world data, so there may be more demand for integration of real-world data into HEOR evidence packages.

In addition to summarizing the points above, the item that we have been tracking even more closely is the expected NICE HTA evaluation guidelines, which were originally due in September 2021, but have now been pushed back to a December 2021 release. These guidelines will directly impact clinical evaluation (CE)/systematic literature review (SLR)/network meta-analysis (NMA) requirements, and PRECISIONheor will be closely monitoring NICE's communications to be able to provide additional guidance to innovators as soon as the report is made public. More to come soon!

---

To learn more about NICE's evaluations and strategy plan, please reach out to Ross Maclean at **ross.maclean@precisionvh.com**.

---

To learn more about PRECISIONheor, visit **www.precisionheor.com**.

PRECISIONheor
a precision value & health team